Evercore ISI Group analyst Elizabeth Anderson reinstates Quest Diagnostics (NYSE:DGX) with a In-Line and announces $165 price target.
Evercore ISI Group Reinstates In-Line on Quest Diagnostics, Announces $165 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.